The Changing Face of Drug Resistant Tuberculosis

The Emory TB/HIV Research Group, Center for AIDS Research (CFAR), the Emory Global Health Institute (EGHI), and the RSPH Departments of Global Health and Epidemiology are pleased to welcome Dr. Dalene von Delft from Cape Town, South Africa as she discusses the evolving epidemic of drug resistant tuberculosis. As a physician and former MDR-TB patient, Dr. von Delft offers unique perspectives from both clinical research and personal experience, and will discuss topics such as access to care, pressing issues, and drug development in the fight against drug resistance.

Wednesday, March 19th
4:00-5:00 PM
CNR Building, Room 1051
Refreshments provided

For additional questions please contact Jonathan Smith (jonathan.p.smith@emory.edu)

About Dr. Dalene von Delft and TB PROOF

Dr. Dalene von Delft was a medical student in South Africa when she contracted multi-drug resistant tuberculosis (MDR-TB). Even with treatment, Dr. von Delft faced only a 42% cure rate of MDR among South Africans. The side effects of the medication were resulting in hearing loss and threatening her medical career. After over a year of treatment, she applied for and was granted ‘compassionate use’ for an experimental drug, bedaquiline, despite a questionably high all-cause mortality rate among those taking the drug. The new drug worked, and today she is fully cured and a practicing emergency-room physician. After her recovery, Dr. von Delft started the non-profit TB PROOF along with her doctor-husband, which was recently awarded the Centre for Global Health and Diplomacy Award for distinguished work in the field of global health diplomacy through USAID earlier this year.